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Purpose: The purpose of this study was to share our experience of transcatheter closure of small 
patent ductus arteriosus (PDA) by using an Amplatzer vascular plug (AVP).
Methods: We reviewed the medical records of 20 patients who underwent transcatheter closure at 
Samsung Medical Center and Sejong General Hospital from January 2008 to August 2012. The size 
and shape of the PDAs were evaluated by performing angiograms, and the PDA size and the AVP 
devices size were compared. 
Results: The mean age of the patients was 54.9±45.7 months old. The PDAs were of type C (n=5), 
type D (n=12), and type E (n=3). The mean pulmonary end diameter of the PDA was 1.7±0.6 mm, 
and the aortic end diameter was 3.6±1.4 mm. The mean length was 7.3±1.8 mm. We used 3 types of 
AVP devices: AVP I (n=5), AVP II (n=7), and AVP IV (n=8). The ratio of AVP size to the pulmonary end 
diameter was 3.37±1.64, and AVP size/aortic end ratio was 1.72±0.97. The aortic end diameter was 
significantly larger in those cases repaired with AVP II than in the others (P=0.002). The AVP size did 
not significantly correlate with the PDA size, but did correlate with smaller ratio of AVP size to aortic end 
diameter (1.10±0.31, P=0.032). 
Conclusion: Transcatheter closure of small PDA with AVP devices yielded satisfactory outcome. AVP II 
was equally effective with smaller size of device, compared to others.
Key words: Patent ductus arteriosus, Cardiac catheterization, Vascular access devices
Corresponding author: Jinyoung Song, MD, PhD
Department of Pediatrics, Samsung Medical Cen-
ter, Sungkyunkwan University School of Medicine, 
81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea 
Tel: +82-2-3410-3538, 
Fax: +82-2-3410-0043, 
E-mail: amyjys@naver.com 
Received: 26 June, 2013
Revised: 24 July, 2013
Accepted: 5 August, 2013
Copyright © 2013 by The Korean Pediatric Society
This is an open-access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Original article
Korean J Pediatr 2013;56(9):396-400
http://dx.doi.org/10.3345/kjp.2013.56.9.396
eISSN 1738-1061•pISSN 2092-7258 Korean J Pediatr
Introduction
It has been more than four decades since transcatheter closure of patent ductus 
arteriosus (PDA) was introduced
1). Occlusion devices and transcatheter closure techniques 
have developed rapidly, and excellent outcomes and low complication rates are the 
standard
2-5). Therefore, transcatheter closure is the preferred treatment method for most 
PDA. Nowadays, Amplatzer ductal occluder (ADO) is the most widely used device for 
PDA closure, and the coil is effective for small PDA. However, the closure of a small 
asymptomatic PDA that is hemodynamically stable is controversial. Nonetheless 
transcatheter closure of PDA is technically easy and safe and even in small ductus, 
infective endocarditis is a concern in untreated cases
6-12). Therefore, the transcatheter 
closure of PDA, regardless of the ductus size, is recommended. Transcatheter closure of 
a small PDA might be technically challenging from the antegrade approach, and the 
type of PDA is important for device selection. The purpose of this study was to share our 
experiences of transcatheter closure of small PDA using Amplatzer vascular plug (AVP; 397 http://dx.doi.org/10.3345/kjp.2013.56.9.396
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AGA Medical Co., Golden Valley, MN, USA). 
Materials and methods
We retrospectively reviewed the medical records of 20 
pediatric patients who underwent transcatheter PDA closure 
at Samsung Medical Center and Sejong General Hospital from 
January 2008 to August 2012. The indications for PDA closure 
were evidence of shunt flow by echocardiogram, regardless 
of PDA size or symptoms, and no evidence of irreversible pul-
monary hypertension due to left to right shunt. Our indications 
for using AVP for transcatheter closure of PDA were as follows: 
1) relatively short ampulla of PDA or tubular shaped, Krichenko 
type (C, D or E) PDA
13), 2) too small pulmonary end for catheter 
passing, 3) tortuous PDA, or 4) when coil for PDA was not 
available. 
The PDA was confirmed by echocardiogram after clinical 
examination of significant or innocent cardiac murmur. 
Postprocedural echocardiogram was repeated on the day after 
catheterization, and again 6 months afterwards. The research 
protocol was approved by the Institutional Review Boards of 
respective institutions.
1. Procedure 
The transcatheter procedure was the same for all patients. 
However, size selection and technique for implantation were 
different due to different types of AVP and different operators. 
Cardiac catheterization was performed under local anesthesia 
or moderate-to-deep sedation. After the aortic arch angiography, 
PDA size was measured at pulmonic communication, aortic 
communication, largest diameter at the middle of ductus, and 
PDA length. Heparin was injected just one time immediately 
after the puncture of femoral artery. Selection of AVP was 
dependent on operators and availability of AVP type on the date 
of procedure. 
AVP I was used prior to AVP II or AVP IV became available in 
Korea. The implantation of AVP I was performed by a retrograde 
approach. PDA size was measured on aortogram, and PDA was 
selected by curved end-hole catheter. If the wire could not pass 
the pulmonary end due to constriction, AVP I was chosen. The 
catheter was positioned inside the tubular portion of PDA. The 
size of AVP I was 1–4 mm larger than the largest diameter of 
tubular portion in PDA. AVP I was deployed inside of PDA.
AVP II implantation was performed by an anterograde 
approach. A floppy-tipped wire traversed the PDA from 
pulmonary artery to descending aorta, and the delivery catheter 
was passed over the wire. AVP II with diameter 2–4 mm larger 
than that of PDA was selected. The first segment or distal 
retention disc of AVP II was deployed in the descending aorta, 
and the devices were pulled back for anchoring compactly in 
aortic ampulla. The main body of AVP II was deployed inside 
of PDA, and the proximal disc was deployed after passing the 
pulmonic end.
AVP IV was selected in cases of small tubular PDA in which 4 
French curved catheter was passed by retrograde approach. The 
implantation was performed with 2–4 mm larger size of AVP 
IV. The first segment of AVP IV was deployed in the pulmonary 
artery, and the device was pulled back for anchoring compactly 
in the distal pulmonary end. The proximal segment of AVP IV 
was deployed within the ductus. 
Upon delivery, the stability of device was tested by pulling and 
pushing gently on the delivery cable. Implantation stability and 
residual leak was evaluated on angiography.
2. Statistics 
Values are reported as mean±standard deviation and ranges. 
We used a nonparametric test, Kruskal-Wallis test for three or 
more variables, and Mann-Whitney U test for two independent 
variables to determine associations of AVP with various factors 
such as age, body weight, PDA size, and PDA/AVP ratio. Simple 
correlation analysis was performed for nonparametric methods 
between AVP and PDA size. A chi-square test was used for 
discrete variables. IBM SPSS ver. 19.0 (IBM Co., Armonk, NY, 
USA) was used for analysis. Null hypotheses of no difference 
were rejected if P values were less than 0.05. 
Table 1. Clinical characteristics of the patients (n=20) 
Characteristic          Value
Age (mo) 54.9±45.7 (9–199)
Gender (male/female)    8 (40)/12 (60)
Body weight (kg) 18.7±11.3 (9–60)
Murmur (+)   9 (45)
PDA type
C   5 (25)
D 12 (60)
E   3 (15)
PDA diameter (mm)
Pulmonary end  1.7±0.6 (1.0–3.2)
Middle  2.3±0.9 (0.9–4.3)
Aortic end  3.6±1.4 (1.2–6.0)
PDA length (mm) 7.3±1.8 (4.3–12.0)
AVP/PDA size ratio
AVP/pulmonary end 3.4±1.6 (1.7–8.0)
AVP/middle of PDA 2.8±1.6 (1.3–7.3)
AVP/Aortic end 1.7±1.0 (0.7–5.0)
Values are presented as mean±standard deviation (range) or number (%).
PDA, patent ductus arteriosus; AVP, Amplatzer vascular plug. http://dx.doi.org/10.3345/kjp.2013.56.9.396
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Results
1. Characteristics of the patients and AVP 
The mean age at catheterization was 54.9±45.7 months (range, 
9 to 199 months), and mean body weight was 18.7±11.3 kg 
(range, 9 to 60 kg). A murmur was audible in 9 patients, 45% of 
all patients (Table 1), but no patient had clinical symptoms from 
PDA. 
Ductal morphology was classified by Krichenko types
10): type 
C (n=5, 25%), type D (n=12, 60%), and type E (n=3, 15%). The 
mean diameter was 1.7±0.6 mm (1.0 to 3.2 mm) at pulmonary 
end, 2.3±0.9 mm (0.9 to 4.3 mm) at the middle of ductus, and 
was 3.6±1.4 mm (1.2 to 6.0 mm) at aortic end. Mean length of 
PDA was 7.3±1.8 mm (4.3 to 12.0 mm). All PDAs were tubular 
(Krichenko types C, D, and E), and the sizes of aortic end were 
less than twice of the size of pulmonary end. The shunt amount 
was not checked because the PDA was small in all angiogram.  
Three types of AVP were used: AVP I (n=5, 25%), AVP II 
(n=7, 35%), AVP IV (n=8, 40%) (Fig.1). There was no significant 
relation between Krichenko type and AVP type used (P>0.05). 
AVP size ranged between 4 mm to 8 mm, and the most-
frequently used size was 4 mm in 10 patients (50%). 
The ratios of AVP size to PDA size were 3.37±1.64 (1.67 to 8.00) 
for AVP/pulmonary end, 2.77±1.60 (1.33 to 7.27) for AVP/middle 
of PDA, and 1.72±0.97 (0.67 to 5.00) for AVP/aortic end. 
2. Correlations of AVP sizes with PDA sizes 
There were no significant differences in PDA size, pulmonary 
end, the middle portion, and length across the types of AVP, but 
AVP types varied significantly according to aortic end diameter 
of PDA (P=0.002) (Table 2). Further analysis revealed that the 
aortic end of a PDA was significantly larger for cases with AVP 
II, when compared with others AVP types, resulting in a more 
conical shaped PDA. The ratios of AVP size to the PDA size 
showed no difference according to types of AVP, except that AVP 
size/aortic end size in the case of AVP II was smaller than others 
(P=0.032). There were no significant differences in age and body 
weight across the AVP types (Table 2).
The size of AVP had no significant correlation with PDA size 
including pulmonary end diameter, diameter at the middle of 
ductus, aortic end diameter, and the length (P>0.05) (Table 3). 
Fig. 1. Angiographies before and after implantation of Amplatzer vascular 
plug I (A, B), II (C, D), and IV (E, F): Long tubular type of patent ductus 
arteriosus and constriction of pulmonic end were visualized. Vascular 
plugs (arrows) were implanted successfully and complete closure was 
achieved.
Table 2. Associations of age, body weight, fluoroscopic time, PDA size, 
PDA/AVP ratio with plug type 
Variable AVP I (n=5) AVP II (n=7) AVP IV (n=8) P value
Age (mo) 38.0±20.1 57.1±65.6 63.0±38.5 0.415
Body weight (kg) 13.6±3.6 21.8±17.5 19.1±7.0 0.298
PDA size (mm)
Pulmonary end 1.7±0.5 1.8±0.7 1.7±0.7 0.913
Middle 2.3±0.7 2.5±1.0 2.0±1.0 0.553
Aortic end 2.5±0.8 5.0±0.7 3.0±1.1 0.002
Length 7.7±1.6 7.1±1.7 7.3±2.3 0.691
AVP/PDA ratio
AVP/pulmonary 2.88±1.22 3.44±1.83 3.62±1.83 0.476
AVP/middle 2.20±1.38 2.54±1.51 3.34±1.80 0.211
AVP/aortic 2.13±1.61 1.10±0.31 2.00±0.62 0.032
Values are presented as mean±standard deviation.
PDA, patent ductus arteriosus; AVP, Amplatzer vascular plug. 
Table 3. Correlation of AVP size with PDA size
Size of AVP Correlation coefficient  
(Spearman rho) P value
Size of PDA
Pulmonary end  0.031 0.897
The middle  0.089 0.708
Aortic end  0.229 0.332
Length 0.045 0.850
PDA, patent ductus arteriosus; AVP, Amplatzer vascular plug. 399 http://dx.doi.org/10.3345/kjp.2013.56.9.396
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3. Procedural failure and complications 
Among the 20 cases, there were no perioperative complications 
to report, and device implantations were successful in all 
patients. Neither residual shunt nor complications such as left 
pulmonary artery obstruction or coarctation of aorta were noted 
on repeat echocardiography at 24 hours and at 6 months post 
procedure. 
Discussion
PDA morphology is highly variable. Krichenko classified the 
shape of PDA into five different types, broadly
13). Depending on 
the size and shape of PDA, various types of devices have been 
used in transcatheter closure of PDA. For most children and 
adult with PDA, safe and effective transcatheter closure of PDA 
has been achieved with ADO
2,5,14,15). Also, varying sizes of PDA 
had been occluded with the use of single or multiple coils
3,16). 
ADO II is a modification of the original ADO and was designed 
for improved occlusion and better positioning. However, ADO II 
was not available in South Korea at that moment. After various 
types of AVP have become available, a few cases of successful 
PDA closure using these devices, even in preterm neonates, have 
been reported
5,15).
In transcatheter closure of small PDA, it is difficult to pass the 
wire from pulmonary artery to descending aorta, and a snaring 
technique is useful for passing the wire through a PDA. In such 
cases, this technically challenge prolongs the procedural duration 
and increases the risk of complications. However, most AVPs 
allow occlusion of a PDA from a retrograde approach. An AVP 
IV device is very useful in small infants because it is possible 
to use 4 French normal catheters to deliver the device. Also, an 
AVP device could be much more efficacious than an ADO device 
in long tubular type PDAs. Most PDAs have a pulmonary end 
constriction, and a multi-segmented type AVP can be anchored 
easily. AVP I is not designed for anchoring but for packing 
into the tubular type PDA. As such, it does not protrude into 
the aorta or pulmonary artery after implantation. However, for 
AVP II or AVP IV, it is difficult to prevent the implanted devices 
from protruding into aorta or pulmonary artery. However, the 
protruding portion is only a small portion of the whole vessel, 
and ductal aneurysm is placed in the pulmonary artery or aorta. 
We believe that there is little risk of hemodynamic instability 
after PDA closure with AVP. In this retrospective review, none of 
the patients exhibited hemodynamic issues after the closure of 
PDA. In our study, AVP I device was used when neither AVP II 
nor AVP IV devices were available. Even though the indication 
for a specific device was not clear, AVP I was preferred for long 
tubular PDAs with very small pulmonic ends. An AVP II device 
was used when PDA appeared too small for ADO but too large 
for AVP IV device. 
The choice of device size is more dependent on the overall 
anatomic features of the PDA: 1) areas of restriction along 
the length of PDA, 2) the presence and size of the ampulla on 
aortic end, 3) the length of PDA, and 4) the proximity to the 
left pulmonary artery. Because PDA is fairly compliant and 
stretchable, it could be safer to choose oversized device. In 
previous publications, the device to vessel size ratio for original 
AVP to tubular type PDA varies from 136%
17) to 228%
18). We 
chose oversized device by measuring the largest tubular portion 
of PDA. We also considered the length of PDA because a larger 
AVP is more likely to protrude into the aortic lumen. Therefore, 
an AVP of 1–2 mm larger than the largest diameter of the PDA 
was selected for a relatively short PDA, whereas an AVP of 2–4 
mm larger was selected for a longer PDA. From our findings, the 
size of AVP can be considered less than 200% of the aortic end 
diameter and 250% of middle portion of small tubular PDA. In a 
report regarding the use of AVP II devices for two cases of PDA 
closure
15), 10-mm AVP II was used for a PDA with a minimum 
diameter of 5.5 mm (180% of the minimum PDA diameter), 
and in the second case, 8-mm AVP II was used in a PDA with 
a minimum diameter of 3.5 mm (230% of the minimum PDA 
diameter). 
Schneider and Moore
19) reviewed the indications for PDA 
closure and supported definite indications in certain patients, 
including those who are symptomatic with left-right shunt and 
those who are asymptomatic but have left heart enlargement. 
They recommended that, even though it was not clear if the 
closure of a small PDA was beneficial, routine closure of any 
PDA in children and young adults appeared reasonable
19). The 
reasons for this recommendation included the risk of infective 
endocarditis and low-or-zero morbidity from closure, especially 
when using a transcatheter device. Fortescue et al.
7) assumed 
that the annual risk of infective endocarditis associated with 
an untreated, asymptomatic PDA would be around 0.001% to 
0.01%, with approximately 0.1% of lifetime risk. After PDA 
closure, this risk for endocarditis decreases is reported to decrease 
to the risk levels experienced by the general population
7,9,10).
All of our patients have small PDAs with or without audible 
cardiac murmur. It was not necessary to check shunt amount 
because of the insignificant amount but no residual shunt was 
checked in any of the patients one day after procedure.
This study was retrospective, and the procedures were 
performed by many operators. For these reasons, we could not 
determine clear indications for types and sizes of AVP, according 
to the PDA size and shape. Nevertheless, we found that AVP was 
useful for closure of small, tubular type PDA. To our knowledge, 
this is the first report describing the experience of transcatheter 
closure of PDA with 3 types of AVP. In the future, well-designed 
prospective studies with long term follow-up are needed to http://dx.doi.org/10.3345/kjp.2013.56.9.396
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identify clear criteria for determining device size.
We experienced very successful transcatheter closure of small 
PDA with AVP I, II and IV devices. AVP II might be preferred due 
to good results with smaller size of device, when compared to 
others.
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